Wednesday, 15 November 2017

FDA approves Ultragenyx drug for rare enzyme disorder

(Reuters) - The U.S. Food and Drug Administration approved on Wednesday a new treatment made by Ultragenyx Pharmaceutical Inc for a rare genetic disorder that can dramatically reduce life expectancy.


No comments:

Post a Comment